Guohua Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guohua Hu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Jiayun Wang
Department of Gynecology of Traditional Chinese Medicine, Shanghai Traditional Chinese Medicine Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
3 shared publicationsJiami Huang
Department of Gynecology of Traditional Chinese Medicine, Shanghai Traditional Chinese Medicine Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2 shared publications- Jing Chen
Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2 shared publications Xu Zhang
Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2 shared publicationsYanan Zhang
Department of Gynecology of Traditional Chinese Medicine, Shanghai Traditional Chinese Medicine Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2 shared publications- Bo Sun
Fangta T.C.M Hospital of Songjiang District Shanghai, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 24 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Mechanism of quercetin in the treatment of endometriosis based on network pharmacology and transcriptome sequencing
This study explores how quercetin may treat endometriosis (EMs) by combining network pharmacology and transcriptome sequencing approaches. Through network pharmacology, 132 shared targets between quercetin and EMs were identified, with KEGG pathway analysis suggesting that the MAPK signaling pathway could be a significant therapeutic target. Transcriptome sequencing revealed that PDGFRB was highly expressed in ectopic endometrial tissue, a finding confirmed by immunohistochemistry (IHC) showing elevated levels of PDGFRB, RAS, RAF1, and ERK1/2 in ectopic lesions. In an EMs mouse model, quercetin treatment led to a marked reduction in ectopic lesion volume, lowered adhesion scores, and decreased expression of PDGFRB, RAS, RAF1, and ERK1/2 in endometrial tissues. Additionally, the knockdown of PDGFRB in endometriosis cells inhibited their proliferation, invasion, and migration, processes critical to EMs pathology. Quercetin treatment further suppressed cell viability and downregulated the protein expression of RAS, phosphorylated RAF1, RAF1, phosphorylated ERK, and ERK1/2. These findings collectively suggest that quercetin exerts its therapeutic effect in endometriosis by regulating the MAPK signaling pathway via PDGFRB, thereby reducing EMs cell proliferation, invasion, and migration. This study provides insights into quercetin’s multi-targeted mechanism of action in endometriosis treatment.
- 24 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessMechanism of quercetin in the treatment of endometriosis based on network pharmacology and transcriptome sequencing
This study explores how quercetin may treat endometriosis (EMs) by combining network pharmacology and transcriptome sequencing approaches. Through network pharmacology, 132 shared targets between quercetin and EMs were identified, with KEGG pathway analysis suggesting that the MAPK signaling pathway could be a significant therapeutic target. Transcriptome sequencing revealed that PDGFRB was highly expressed in ectopic endometrial tissue, a finding confirmed by immunohistochemistry (IHC) showing elevated levels of PDGFRB, RAS, RAF1, and ERK1/2 in ectopic lesions. In an EMs mouse model, quercetin treatment led to a marked reduction in ectopic lesion volume, lowered adhesion scores, and decreased expression of PDGFRB, RAS, RAF1, and ERK1/2 in endometrial tissues. Additionally, the knockdown of PDGFRB in endometriosis cells inhibited their proliferation, invasion, and migration, processes critical to EMs pathology. Quercetin treatment further suppressed cell viability and downregulated the protein expression of RAS, phosphorylated RAF1, RAF1, phosphorylated ERK, and ERK1/2. These findings collectively suggest that quercetin exerts its therapeutic effect in endometriosis by regulating the MAPK signaling pathway via PDGFRB, thereby reducing EMs cell proliferation, invasion, and migration. This study provides insights into quercetin’s multi-targeted mechanism of action in endometriosis treatment.
- Open Access
- 21 February 2023
- Published by Wiley in Thoracic Cancer
- Vol. 14 (10) , 881-892
Circ_0001667 accelerates breast cancer proliferation and angiogenesis through regulating CXCL10 expression by sponging miR‐6838‐5p
Background: An increasing number of circular RNAs (circRNAs) have been shown to play an important role in the tumorigenesis of breast cancer. The aim of this study was to investigate the expression and function of circ_0001667 and its potential molecular mechanisms in breast cancer.Methods: The expression levels of circ_0001667, miR‐6838‐5p and CXC chemokine ligand 10 (CXCL10) in breast cancer tissues and cells were detected by quantitative real‐time PCR. Cell counting kit‐8 assay, EdU assay, flow cytometry, colony formation and tube formation assays were used to detect cell proliferation and angiogenesis. The binding relationship between miR‐6838‐5p and circ_0001667 or CXCL10 was predicted using the starBase3.0 database and verified by dual‐luciferase reporter gene assay, RIP and RNA pulldown. Animal experiments were performed to assess the function of circ_0001667 knockdown on breast cancer tumor growth.Results: Circ_0001667 was highly expressed in breast cancer tissues and cells, and its knockdown inhibited proliferation and angiogenesis of breast cancer cells. Circ_0001667 sponged miR‐6838‐5p, and inhibition of miR‐6838‐5p reversed the inhibitory effect of silencing circ_0001667 on proliferation and angiogenesis of breast cancer cells. MiR‐6838‐5p targeted CXCL10, and overexpression of CXCL10 reverses the effect of miR‐6838‐5p overexpression on breast cancer cell proliferation and angiogenesis. In addition, circ_0001667 interference also reduced breast cancer tumor growth in vivo.Conclusion: Circ_0001667 is involved in breast cancer cell proliferation and angiogenesis through regulation of the miR‐6838‐5p/CXCL10 axis.
- 21 February 2023
- Published by Wiley in Thoracic Cancer
- Vol. 14 (10) , 881-892
Open AccessCirc_0001667 accelerates breast cancer proliferation and angiogenesis through regulating CXCL10 expression by sponging miR‐6838‐5p
Background: An increasing number of circular RNAs (circRNAs) have been shown to play an important role in the tumorigenesis of breast cancer. The aim of this study was to investigate the expression and function of circ_0001667 and its potential molecular mechanisms in breast cancer.Methods: The expression levels of circ_0001667, miR‐6838‐5p and CXC chemokine ligand 10 (CXCL10) in breast cancer tissues and cells were detected by quantitative real‐time PCR. Cell counting kit‐8 assay, EdU assay, flow cytometry, colony formation and tube formation assays were used to detect cell proliferation and angiogenesis. The binding relationship between miR‐6838‐5p and circ_0001667 or CXCL10 was predicted using the starBase3.0 database and verified by dual‐luciferase reporter gene assay, RIP and RNA pulldown. Animal experiments were performed to assess the function of circ_0001667 knockdown on breast cancer tumor growth.Results: Circ_0001667 was highly expressed in breast cancer tissues and cells, and its knockdown inhibited proliferation and angiogenesis of breast cancer cells. Circ_0001667 sponged miR‐6838‐5p, and inhibition of miR‐6838‐5p reversed the inhibitory effect of silencing circ_0001667 on proliferation and angiogenesis of breast cancer cells. MiR‐6838‐5p targeted CXCL10, and overexpression of CXCL10 reverses the effect of miR‐6838‐5p overexpression on breast cancer cell proliferation and angiogenesis. In addition, circ_0001667 interference also reduced breast cancer tumor growth in vivo.Conclusion: Circ_0001667 is involved in breast cancer cell proliferation and angiogenesis through regulation of the miR‐6838‐5p/CXCL10 axis.